Synopsis
Synopsis
0
VMF
0
Australia
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 2 Propylpentanoic Acid
2. 2-propylpentanoic Acid
3. Calcium Valproate
4. Convulsofin
5. Depakene
6. Depakine
7. Depakote
8. Dipropyl Acetate
9. Divalproex
10. Divalproex Sodium
11. Ergenyl
12. Magnesium Valproate
13. Propylisopropylacetic Acid
14. Semisodium Valproate
15. Valproate
16. Valproate Calcium
17. Valproate Sodium
18. Valproic Acid
19. Valproic Acid, Sodium Salt (2:1)
20. Vupral
1. Sodium 2-propylpentanoate
2. 1069-66-5
3. Valproate Sodium
4. Valproic Acid Sodium Salt
5. Valproic Acid Sodium
6. Depacon
7. Sodium 2-propylvalerate
8. Epilim
9. Valproic Acid, Sodium Salt
10. Pentanoic Acid, 2-propyl-, Sodium Salt
11. 2-propylvaleric Acid Sodium Salt
12. Valerin
13. 2-propylpentanoic Acid Sodium Salt
14. Valproic Acid Sodium Salt (1:1)
15. Valproic Acid (sodium Salt)
16. Selenica
17. Abbott 44090
18. Valproate Sodium [usan]
19. Valproate
20. Valproic Acid, Sodium
21. Valproic Acid Sodium Salt (sodium Valproate)
22. Sodium;2-propylpentanoate
23. Mfcd00078604
24. 5vom6gyj0d
25. Abbott-44090
26. Chebi:9925
27. Eurekene
28. Labazene
29. Orfiril
30. Kw-6066n
31. Nsc-732626
32. Nsc-757376
33. Depakene (tn)
34. Natrium Valproat
35. Valproate Sodium (usan)
36. A-44090
37. Dipropylacetate Sodium
38. Sodium Dipropylacetate
39. Sodium Bispropylacetate
40. Chembl433
41. Valproinsaeure, Natrium
42. Sodium N-dipropylacetate
43. 2-propylpentanoic Acid Sodium
44. Smr000875243
45. Sodium 2-n-propyl-pentanoate
46. Kw 6066n
47. Einecs 213-961-8
48. Unii-5vom6gyj0d
49. Valeric Acid, 2-propyl-, Sodium Salt
50. Natrii Valproas
51. Valproate Sodium [usan:usp]
52. Valproicacidsodium
53. Selenica (tn)
54. Valproic Acid (sodium)
55. Lopac-p-4543
56. Sodium Valproate (jp17)
57. Dsstox_cid_17072
58. Dsstox_rid_79301
59. Dsstox_gsid_37072
60. Schembl35027
61. Mls001332431
62. Mls001332432
63. Mls002153189
64. Spectrum1500606
65. Sodium Valproate [jan]
66. Dtxsid5037072
67. Valproate Sodium [vandf]
68. Hms500n15
69. Valproic Acid Sodium Salt, 98%
70. Sodium Valproate [mart.]
71. Sodium Valproate [who-ip]
72. Valproate Sodium [who-dd]
73. Hms1921i21
74. Hms2092c12
75. Hms2230e16
76. Hms3262b20
77. Hms3369l11
78. Hms3648a12
79. Hms3654i14
80. Hms3872g13
81. Hms3884e05
82. Bcp02888
83. Tox21_302623
84. Tox21_500889
85. Ccg-40071
86. Hy-10585a
87. S1168
88. 2-propyl-pentanoic Acid, Sodium Salt
89. Akos005066057
90. Valproate Sodium [orange Book]
91. Ac-8391
92. Ccg-208088
93. Ccg-266330
94. Cs-1764
95. Lp00889
96. Natrii Valproas [who-ip Latin]
97. Nsc 732626
98. Nsc 757376
99. Sodium Valproate [ep Monograph]
100. Valproate Sodium [usp Impurity]
101. Ncgc00016192-01
102. Ncgc00016192-02
103. Ncgc00016192-03
104. Ncgc00016192-04
105. Ncgc00094208-01
106. Ncgc00094208-02
107. Ncgc00094208-03
108. Ncgc00167849-01
109. Ncgc00256651-01
110. Ncgc00261574-01
111. As-13150
112. Sy058189
113. 2-propylpentanoic Acid Sodium Salt (1:1)
114. Bcp0726000316
115. Cas-1069-66-5
116. Db-059527
117. Sodium 2-propylpentanoate [who-ip]
118. Eu-0100889
119. Ft-0633278
120. S0894
121. Sw219169-2
122. D00710
123. H11308
124. P 4543
125. Valproic Acid Sodium Salt (1:1) [mi]
126. Pentanoic Acid, 2-propyl-, Sodium Salt (1:1)
127. Valproic Acid, Sodium Salt - Cas 1069-66-5
128. Q-201918
129. Q4347890
130. Sodium Valproate, British Pharmacopoeia (bp) Reference Standard
131. Sodium Valproate, European Pharmacopoeia (ep) Reference Standard
132. Sodium Valproate, 2-propylpentanoic Acid . Na, Sodium 2-propylpentanoate
| Molecular Weight | 166.19 g/mol |
|---|---|
| Molecular Formula | C8H15NaO2 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 5 |
| Exact Mass | 166.09697400 g/mol |
| Monoisotopic Mass | 166.09697400 g/mol |
| Topological Polar Surface Area | 40.1 Ų |
| Heavy Atom Count | 11 |
| Formal Charge | 0 |
| Complexity | 98.3 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 4 | |
|---|---|
| Drug Name | Depacon |
| PubMed Health | Valproate Sodium (Injection) |
| Drug Classes | Anticonvulsant |
| Drug Label | Depacon (valproate sodium) is the sodium salt of valproic acid designated as sodium 2-propylpentanoate. Valproate sodium has the following structure:Valproate sodium has a molecular weight of 166.2. It occurs as an essentially white and odorless, cry... |
| Active Ingredient | Valproate sodium |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 100mg base/ml |
| Market Status | Prescription |
| Company | Abbvie |
| 2 of 4 | |
|---|---|
| Drug Name | Valproate sodium |
| PubMed Health | Valproate Sodium (Injection) |
| Drug Classes | Anticonvulsant |
| Drug Label | Valproate sodium injection, USPis the sodium salt of valproic acid designated as sodium 2-propylpentanoate. Valproate sodium has the following structure:Valproate sodium has a molecular weight of 166.2. It occurs as an essentially white and odorles... |
| Active Ingredient | Valproate sodium |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 100mg base/ml |
| Market Status | Prescription |
| Company | Bedford; Hikma Farmaceutica; Fresenius Kabi Usa |
| 3 of 4 | |
|---|---|
| Drug Name | Depacon |
| PubMed Health | Valproate Sodium (Injection) |
| Drug Classes | Anticonvulsant |
| Drug Label | Depacon (valproate sodium) is the sodium salt of valproic acid designated as sodium 2-propylpentanoate. Valproate sodium has the following structure:Valproate sodium has a molecular weight of 166.2. It occurs as an essentially white and odorless, cry... |
| Active Ingredient | Valproate sodium |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 100mg base/ml |
| Market Status | Prescription |
| Company | Abbvie |
| 4 of 4 | |
|---|---|
| Drug Name | Valproate sodium |
| PubMed Health | Valproate Sodium (Injection) |
| Drug Classes | Anticonvulsant |
| Drug Label | Valproate sodium injection, USPis the sodium salt of valproic acid designated as sodium 2-propylpentanoate. Valproate sodium has the following structure:Valproate sodium has a molecular weight of 166.2. It occurs as an essentially white and odorles... |
| Active Ingredient | Valproate sodium |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 100mg base/ml |
| Market Status | Prescription |
| Company | Bedford; Hikma Farmaceutica; Fresenius Kabi Usa |
Anticonvulsants
Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)
Antimanic Agents
Agents that are used to treat bipolar disorders or mania associated with other affective disorders. (See all compounds classified as Antimanic Agents.)
Enzyme Inhibitors
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)
GABA Agents
Substances used for their pharmacological actions on GABAergic systems. GABAergic agents include agonists, antagonists, degradation or uptake inhibitors, depleters, precursors, and modulators of receptor function. (See all compounds classified as GABA Agents.)
API SUPPLIERS
Jai Radhe Sales is your partner for all your sourcing needs.
EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.
Registrant Name : Bukwang Pharmaceutical Co., Ltd.
Registration Date : 2022-01-10
Registration Number : 20210604-209-J-1010(1)
Manufacturer Name : Sanofi Chimie
Manufacturer Address : Chem'pôle 64 Avenue du Lac, 64150 MOURENX, France
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Certificate Number : CEP 2004-198 - Rev 05
Issue Date : 2024-02-06
Type : Chemical
Substance Number : 678
Status : Valid
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Chynops Pharma is an ideal sourcing partner for high-quality APIs, advanced intermediates, speciality chemicals & excipients.
SCI Pharmtech offers high-quality, cost-effective APIs, advanced intermediates, & custom products with global expertise and precision.
GDUFA
DMF Review : Reviewed
Rev. Date : 2019-11-25
Pay. Date : 2019-09-18
DMF Number : 33350
Submission : 2019-09-24
Status : Active
Type : II
Certificate Number : R1-CEP 2004-302 - Rev 04
Issue Date : 2019-07-26
Type : Chemical
Substance Number : 678
Status : Valid
Registration Number : 229MF10059
Registrant's Address : No. 61, Ln. 309, Haihu N. Rd. , Luzhu Dist. , Taoyuan City 33856, Taiwan
Initial Date of Registration : 2017-03-03
Latest Date of Registration : --
NDC Package Code : 68108-0233
Start Marketing Date : 2004-06-23
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Aging Life Science Co., Ltd.
Registration Date : 2021-10-19
Registration Number : 20211019-209-J-1049
Manufacturer Name : SCI Pharmtech, Inc.
Manufacturer Address : No.61, Ln.309, Haihu N. Rd., Luzhu Dist., Taoyuan City 33856, Taiwan
| Available Reg Filing : CN |
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 11786
Submission : 1995-12-24
Status : Active
Type : II
Certificate Number : R1-CEP 2004-250 - Rev 01
Issue Date : 2012-07-05
Type : Chemical
Substance Number : 678
Status : Valid
Registration Number : 304MF10081
Registrant's Address : Snijderstraat 6,2222 BA, Katwijk, ZH The Netherlands
Initial Date of Registration : 2022-05-25
Latest Date of Registration : --
NDC Package Code : 17349-0009
Start Marketing Date : 1995-12-24
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Lee Sung International Co., Ltd.
Registration Date : 2021-08-31
Registration Number : 20210323-209-J-611(1)
Manufacturer Name : Katwijk Chemie BV
Manufacturer Address : Snijderstraat 6, Katwijk ZH, 2222BA, Netherlands
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 17225
Submission : 2004-03-05
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 5159
Submission : 1983-12-05
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 18016
Submission : 2005-01-19
Status : Inactive
Type : II
Certificate Number : R1-CEP 2004-027 - Rev 04
Issue Date : 2020-12-16
Type : Chemical
Substance Number : 678
Status : Valid
Date of Issue : 2022-09-30
Valid Till : 2025-09-10
Written Confirmation Number : WC-0243
Address of the Firm :
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Sodium Valproate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Sodium Valproate, including repackagers and relabelers. The FDA regulates Sodium Valproate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Sodium Valproate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Sodium Valproate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Sodium Valproate supplier is an individual or a company that provides Sodium Valproate active pharmaceutical ingredient (API) or Sodium Valproate finished formulations upon request. The Sodium Valproate suppliers may include Sodium Valproate API manufacturers, exporters, distributors and traders.
click here to find a list of Sodium Valproate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Sodium Valproate DMF (Drug Master File) is a document detailing the whole manufacturing process of Sodium Valproate active pharmaceutical ingredient (API) in detail. Different forms of Sodium Valproate DMFs exist exist since differing nations have different regulations, such as Sodium Valproate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Sodium Valproate DMF submitted to regulatory agencies in the US is known as a USDMF. Sodium Valproate USDMF includes data on Sodium Valproate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Sodium Valproate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Sodium Valproate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Sodium Valproate Drug Master File in Japan (Sodium Valproate JDMF) empowers Sodium Valproate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Sodium Valproate JDMF during the approval evaluation for pharmaceutical products. At the time of Sodium Valproate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Sodium Valproate suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Sodium Valproate Drug Master File in Korea (Sodium Valproate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Sodium Valproate. The MFDS reviews the Sodium Valproate KDMF as part of the drug registration process and uses the information provided in the Sodium Valproate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Sodium Valproate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Sodium Valproate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Sodium Valproate suppliers with KDMF on PharmaCompass.
A Sodium Valproate CEP of the European Pharmacopoeia monograph is often referred to as a Sodium Valproate Certificate of Suitability (COS). The purpose of a Sodium Valproate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Sodium Valproate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Sodium Valproate to their clients by showing that a Sodium Valproate CEP has been issued for it. The manufacturer submits a Sodium Valproate CEP (COS) as part of the market authorization procedure, and it takes on the role of a Sodium Valproate CEP holder for the record. Additionally, the data presented in the Sodium Valproate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Sodium Valproate DMF.
A Sodium Valproate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Sodium Valproate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Sodium Valproate suppliers with CEP (COS) on PharmaCompass.
A Sodium Valproate written confirmation (Sodium Valproate WC) is an official document issued by a regulatory agency to a Sodium Valproate manufacturer, verifying that the manufacturing facility of a Sodium Valproate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Sodium Valproate APIs or Sodium Valproate finished pharmaceutical products to another nation, regulatory agencies frequently require a Sodium Valproate WC (written confirmation) as part of the regulatory process.
click here to find a list of Sodium Valproate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Sodium Valproate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Sodium Valproate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Sodium Valproate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Sodium Valproate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Sodium Valproate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Sodium Valproate suppliers with NDC on PharmaCompass.
Sodium Valproate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Sodium Valproate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Sodium Valproate GMP manufacturer or Sodium Valproate GMP API supplier for your needs.
A Sodium Valproate CoA (Certificate of Analysis) is a formal document that attests to Sodium Valproate's compliance with Sodium Valproate specifications and serves as a tool for batch-level quality control.
Sodium Valproate CoA mostly includes findings from lab analyses of a specific batch. For each Sodium Valproate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Sodium Valproate may be tested according to a variety of international standards, such as European Pharmacopoeia (Sodium Valproate EP), Sodium Valproate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Sodium Valproate USP).
LOOKING FOR A SUPPLIER?
